InMed Pharmaceuticals: Notable Launches Of High-Value Rare Cannabinoids
Edison Group | May 03, 2022 12:15
InMed Pharmaceuticals Inc (NASDAQ:INM) continues its transition from a pure-play pharma R&D firm to one also benefiting from commercial sales into the health and wellness market. Product launches of high-value, rare cannabinoids into this market should provide the majority of its revenue in the near future. INM also made notable advances in its pharmaceutical drug development programs, including its ongoing 755-201-EB Phase II trial and preparing for an FDA pre-investigational new drug meeting on glaucoma drug candidate INM-088. We expect to see a different InMed going forward, one that offers near-term revenue generation combined with the longer-term value of its pharma drug development programs.
Share price performance
Business description
InMed Pharmaceuticals, a North American-based biopharmaceutical company, is a leader in the research, development, manufacturing and commercialization of rare cannabinoids. Together with its subsidiary BayMedica, the company has multiple and flexible cannabinoid manufacturing capabilities to serve a spectrum of consumer markets, including pharmaceutical and health and wellness.
Health and wellness product launches
With its recent BayMedica acquisition, InMed expanded its focus to the health and wellness market, with several recent and upcoming product launches generating its first revenues. In addition to access to the manufacturing of naturally occurring cannabinoids, BayMedica brought a large library of rare cannabinoid analogs, providing an additional commercial opportunity. As well as cannabichromene (CBC) and cannabicitran (CBT), the latter of which was recently launched and had its first B2B sales in Q1 of CY22, INM launched cannabidivarin (CBDV) and plans to launch tetrahydrocannabivarin (THCV) in Q2 CY22, both of which have potential health indications and are considered by management to be high-demand cannabinoids.
INM-755 and INM-088: Notable advances
Get The App
InMed has made notable advances in both preclinical and clinical phases of its pharmaceutical development platform. Enrollment for the 755-201-EB trial (to treat epidermolysis bullosa (EB)) began in December and management expects to complete it during CY22. Also in December, INM announced a peer-reviewed scientific article regarding using cannabinol (CBN; the API in INM-755) to treat glaucoma. It also continued advancing INM-088 towards human trials, as it prepares for its pre-investigational new drug meeting with the US FDA.
Valuations: $6 (base), $16 (bull), $1.5 (bear) per share
We have updated our valuation to consider a range of scenarios as well as accounting for the BayMedica acquisition. Our risk-adjusted per basic share valuations are US$6.0 (base), US$16.0 (bull), and US$1.5 (bear), versus the previous US$20.53. The key factors influencing our valuation are the market share InMed can capture with its biosynthesis platform and its EB treatment, projected sales for its cannabinoid health & wellness products, and rolling our model forward.
Click on the PDF below to read the full report:
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.